Table 6.
Fife-year oncological outcomes in different PC series for the treatment of muscle-invasive bladder-cancer.
| Reference | Year of publication | Number of PC patients | Age | OS | CSS | RFS |
|---|---|---|---|---|---|---|
| Ebbing et al. | 2018 | 27 | Median 66.0 (IQR 56.0–76.0) | 53.7.0% | 67.9% | 55.8%1 |
| Knoedler et al.7 | 2012 | 86 | Median 68.5 (IQR 50.9–72.3) | 53.0% | 65.0% | No data |
| Zhang et al.29 | 2010 | 100 | Mean 65.7 (SD ± 12.7) | No data | 68.0% | 29.0%1 |
| Ma et al.23 | 2013 | 101 | Median 69.0 (range 24.0–84.0) | 58.0% | 65.0% | 50.0%2 |
| Kassouf et al.9 | 2006 | 37 | Median 69.9 (range 40.0–82.0) | 67.0% | 87.0% | 39.9%2 |
| Holzbeierlein et al.8 | 2004 | 58 | Mean 65.5 (range 16.0–91.0) | 69.0% | No data | No data |
| Smaldone et al.24 | 2008 | 25 | Mean 65.1 (SD ± 9.8) | 70.0% | 84.0% | 64.0%2 |
| Koga et al.30 | 2011 | 46 | Median 74.0 (IQR 63.0–81.0) | No data | 100.0% | 77.0%1 |
(OS) overall survival, (CSS) cancer-specific survival, (RFS) recurrence-free survival, (IQR) interquartile range, (SD) standard deviation.
1Recurrence defined as local recurrence within the bladder (non-muscle invasive and/or muscle-invasive).
2Recurrence defined as local recurrence within the bladder (non-muscle invasive and/or muscle-invasive) and/or development of pelvic or distant metastasis.